Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...

Gilead Sciences, Inc. today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% (30 out of 37) of participants with primary biliary ...

KubeCon + CloudNativeCon North America 2024 ? The Cloud Native Computing Foundation® (CNCF®), which builds sustainable ecosystems for cloud native software, is pleased to announce the first KubeCon + ...

Q4 2024 Earnings Call Transcript November 14, 2024 Operator: Good morning, ladies and gentlemen, and welcome to the Suburban ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good morning, and welcome to Fulcrum Therapeutics Third Quarter ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 202 ...

KAPALUA, Hawai‘i, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Maui Land & Pineapple Company, Inc. (NYSE: MLP) today reported financial results covering the nine month period ended September 30, 2024.

Maui Land & Pineapple Company, Inc. (NYSE: MLP) today reported financial results covering the nine month period ended September 30, 2024. "Our third-quarter ...

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the ...

Good morning, ladies and gentlemen, and welcome to the Suburban Propane Partners Fourth Quarter and Fiscal Year-End Earnings Conference Call. (Operator Instructions) This call is being recorded on ...

Operator: Good morning, ladies and gentlemen, and welcome to the BK Technologies Corporation Conference Call for the Third ...

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.